Groot Koerkamp Bas, Wiggers Jimme K, Allen Peter J, Besselink Marc G, Blumgart Leslie H, Busch Olivier R C, Coelen Robert J, D'Angelica Michael I, DeMatteo Ronald P, Gouma Dirk J, Kingham T Peter, Jarnagin William R, van Gulik Thomas M
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Department of Surgery, Academic Medical Center Amsterdam, Amsterdam, The Netherlands.
J Am Coll Surg. 2015 Dec;221(6):1041-9. doi: 10.1016/j.jamcollsurg.2015.09.005. Epub 2015 Sep 15.
The aim of this study was to investigate the rate and pattern of recurrence after curative intent resection of perihilar cholangiocarcinoma (PHC).
Patients were included from 2 prospectively maintained databases. Recurrences were categorized by site. Time to recurrence and recurrence-free survival (RFS) were estimated using the Kaplan-Meier method. Cox proportional hazards modeling was used to identify independent poor prognostic factors.
Between 1991 and 2012, 306 consecutive patients met inclusion criteria. Median overall survival was 40 months. A recurrence was diagnosed in 177 patients (58%). An initial local recurrence was found in 26% of patients: liver hilum (11%), hepaticojejunostomy (8%), liver resection margin (8%), or distal bile duct remnant (2%). An initial distant recurrence was observed in 40% of patients: retroperitoneal lymph nodes (14%), intrahepatic away from the resection margin (13%), peritoneum (12%), and lungs (8%). Only 18% of patients had an isolated initial local recurrence. The estimated overall recurrence rate was 76% at 8 years. After a recurrence-free period of 5 years, 28% of patients developed a recurrence in the next 3 years. Median RFS was 26 months. Independent prognostic factors for RFS were resection margin, lymph node status, and tumor differentiation. Only node-positive PHC precluded RFS beyond 7 years.
Perihilar cholangiocarcinoma will recur in most patients (76%) after resection, emphasizing the need for better adjuvant strategies. The high recurrence rate of up to 8 years justifies prolonged surveillance. Only patients with an isolated initial local recurrence (18%) may have benefited from a more extensive resection or liver transplantation. Node-positive PHC appears incurable.
本研究旨在调查肝门部胆管癌(PHC)根治性切除术后的复发率及复发模式。
患者来自2个前瞻性维护的数据库。复发按部位分类。采用Kaplan-Meier法估计复发时间和无复发生存期(RFS)。使用Cox比例风险模型识别独立的不良预后因素。
1991年至2012年期间,306例连续患者符合纳入标准。中位总生存期为40个月。177例患者(58%)被诊断为复发。26%的患者出现初始局部复发:肝门(11%)、肝空肠吻合口(8%)、肝切除边缘(8%)或远端胆管残端(2%)。40%的患者出现初始远处复发:腹膜后淋巴结(14%)、肝内远离切除边缘(13%)、腹膜(12%)和肺(8%)。仅18%的患者有孤立的初始局部复发。8年时估计的总复发率为76%。在5年无复发期后,28%的患者在接下来3年内复发。中位RFS为26个月。RFS的独立预后因素为切除边缘、淋巴结状态和肿瘤分化。仅淋巴结阳性的PHC患者RFS不超过7年。
大多数患者(76%)肝门部胆管癌切除术后会复发,强调需要更好的辅助治疗策略。高达8年的高复发率证明需要延长监测时间。仅孤立初始局部复发的患者(18%)可能从更广泛的切除或肝移植中获益。淋巴结阳性的PHC似乎无法治愈。